Donor ABCB1 3435 C>T Genetic Polymorphisms Influence Early Renal Function in Kidney Transplant Recipients Treated with Tacrolimus
L Yan, Y Li, JT Tang, YF An, LL Wang… - Pharmacogenomics, 2016 - Taylor & Francis
Aim: Determine the effect of genetic variants of donors and recipients on early renal function
and tacrolimus pharmacokinetics in kidney transplant recipients. Patients & methods: We …
and tacrolimus pharmacokinetics in kidney transplant recipients. Patients & methods: We …
[HTML][HTML] CYP3A5 and ABCB1 genotype influence tacrolimus and sirolimus pharmacokinetics in renal transplant recipients
Y Li, L Yan, Y Shi, Y Bai, J Tang, L Wang - Springerplus, 2015 - Springer
Abstract CYP3A5 and ABCB1 polymorphisms have been shown to influence tacrolimus
blood concentrations and dose requirements, but the conclusion in the current reports were …
blood concentrations and dose requirements, but the conclusion in the current reports were …
The influence of genetic polymorphisms of cytochrome P450 3A5 and ABCB1 on starting dose- and weight-standardized tacrolimus trough concentrations after …
M Mourad, P Wallemacq, M De Meyer… - Clinical Chemistry and …, 2006 - degruyter.com
Abstract Background: Cytochrome P450 3A5 (CYP3A5) and ABCB1 polymorphisms have
been shown to influence tacrolimus (Tc) blood concentrations in the stable phase after …
been shown to influence tacrolimus (Tc) blood concentrations in the stable phase after …
Influence of ABCB1 polymorphisms and haplotypes on tacrolimus nephrotoxicity and dosage requirements in children with liver transplant
AF Hawwa, PJ McKiernan, M Shields… - British journal of …, 2009 - Wiley Online Library
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT• Currently tacrolimus is the mainstay
of immunosuppression for most children undergoing liver transplantation (LT).• The clinical …
of immunosuppression for most children undergoing liver transplantation (LT).• The clinical …
Liver transplant patient carriers of polymorphism Cyp3a5* 1 donors may need more doses of tacrolimus from the first month after transplantation
A Argudo, JMG De Aledo, P Alía, P Ramírez… - Transplantation …, 2015 - Elsevier
Background The aim of this work was to evaluate the CYP3A5: CYP3A5* 1/CYP3A5* 3
(6986A> G) polymorphism related to the pharmacokinetic characteristics of tacrolimus …
(6986A> G) polymorphism related to the pharmacokinetic characteristics of tacrolimus …
CYP3A5 and ABCB1 polymorphisms in donor and recipient: impact on Tacrolimus dose requirements and clinical outcome after renal transplantation
F Glowacki, A Lionet, D Buob… - Nephrology Dialysis …, 2011 - academic.oup.com
Background. The effect of potentially relevant genetic polymorphisms, CYP3A5 6986A> G
and ABCB1 3435C> T, on Tacrolimus pharmacokinetics and graft clinical outcome was …
and ABCB1 3435C> T, on Tacrolimus pharmacokinetics and graft clinical outcome was …
CYP3A5* 1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation
M Goto, S Masuda, T Kiuchi, Y Ogura… - Pharmacogenetics …, 2004 - journals.lww.com
Objectives Tacrolimus is widely used for immunosuppressive therapy after organ
transplantation, but its pharmacokinetics shows such great interindividual variation that …
transplantation, but its pharmacokinetics shows such great interindividual variation that …
Influence of CYP3A5 6986A > G and ABCB1 3435C > T Polymorphisms on Adverse Events Associated With Tacrolimus in Jordanian Pediatric Renal Transplant …
SKB Sy, RP Singh, S Shilbayeh… - Clinical …, 2013 - Wiley Online Library
The aim of the study is to investigate the influence of ABCB1 (3435) and CYP3A5 (6986)
polymorphisms, tacrolimus troughs and clinical factors on the time of adverse events …
polymorphisms, tacrolimus troughs and clinical factors on the time of adverse events …
Influence of donor and recipient CYP3A4, CYP3A5, and ABCB1 genotypes on clinical outcomes and nephrotoxicity in liver transplant recipients
M Debette-Gratien, JB Woillard, N Picard… - …, 2016 - journals.lww.com
Background This study investigated the influence of the CYP3A4* 22, CYP3A5* 3, and
ABCB1 exons 12, 21, and 26 polymorphisms in donors and recipients on clinical outcomes …
ABCB1 exons 12, 21, and 26 polymorphisms in donors and recipients on clinical outcomes …
Population pharmacokinetics of tacrolimus and CYP3A5, MDR1 and IL‐10 polymorphisms in adult liver transplant patients
D Li, W Lu, JY Zhu, J Gao, YQ Lou… - Journal of clinical …, 2007 - Wiley Online Library
Background and objective: Tacrolimus, an immunosuppressant widely used after liver
transplantation, is characterized by a large inter‐individual variability in its …
transplantation, is characterized by a large inter‐individual variability in its …